DreaMed AI Helps Florida Woman Manage Type-1 Diabetes

Ashlynn Mills, a type-1 diabetes patient from Florida, was able to leverage a virtual clinic to manage her condition during the pandemic.

This global health crisis has brought a challenging time to the world when almost every move is limited, including hospital visits and check-ups.

Unfortunately, there is no endocrinologist within miles of Mills' town, and the clinic where she gets checked is two-and-a-half-hours away from home.

As a healthcare worker herself, she started to be involved in telemedicine when the COVID-19 began spreading.

Mills said most of the adult endocrinologists seem trapped "in the stone ages a little bit." She added, if her endocrinologist stops offering her telemedicine, she'd love for DreaMed to be the replacement for her current doctor. It would be nice, and she continued, "To do telemedicine and do not have to drive" for hours to be checked by a professional.

ALSO READ: DreaMed to Participate in $5Million Study for Virtual Healthcare for Diabetic Patients

DreaMed's Telemedicine

Her involvement in telemedicine made Mills realize how easy it could be, and there should not be any reason for her diabetes not to be remotely managed. With just a quick search online, she found DreaMead's virtual service.

To respond to COVID-19, DreaMed set out its Artificial Intelligence-based virtual service, an online portal for patients to be onboarded and get personalized consultation and professional care to manage their diabetes.

A first of its kind FDA-cleared solution, DreaMed, has instantly become an essential telemedicine solution designed for the "immune-compromised diabetes population.

Patients, particularly those living in rural communities like Mills, can now access dependable and customized diabetes treatments in their homes' comfort. They don't have to go out to travel miles away from home and risk their safety.

The success of the AI technology for insulin recommendations of DreaMed was validated in a clinical test which Nature Medicine recently published, which featured prestigious universities, including Harvard and Yale.

ALSO READ: Childhood Syndrome Linked to COVID-19 Leads to Changes in the Immune System

DreaMed Diabetes AI

DreaMed Diabetes AI is designed to improve diabetes patients' lives already dependent on insulin and their caregivers, empowering them with ground-breaking customized treatment and decision support technology.

DreaMed was established as a spin-off of the DREAM International Consortium in 2014 for the insulin control technology behind Glucositter to be commercialized.

Then, DreaMed Diabetes revolutionized with "artificial pancreas studies" at homes of patients, after which it turned out to be the pioneering firm in the world to get a CE Mark certification for its artificial pancreas system.

In addition, in devising the adaptive "MD Logic cognitive technology," underpinning Advisor and Glucositter, this latest innovation for diabetes managed and ran multicentre, multinational, and large-scale clinical tests with complete results published in various popular health journals.

The Advisor of DreaMEd Diabetes is presently being used in top clinical centers in the European Union and the United States, where the technology's safety and effectiveness have been clearly presented.

Furthermore, the solution of DreaMed is being utilized both virtually and physically as the firm has expanded its solution and is presently being set out at clinics across the US, specifically at Stanford, NYU, Texas Children's Hospital Billings, and the University of Florida, among others.

IN CASE YOU MISSED IT: Case Report at Children's National Hospital Raises Concern for Resistance to Antibiotic

Check out more news and information on Diabetes on MD News Daily.

© MD News Daily.